Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "5-Hydroxytryptophan" patented technology

5-Hydroxytryptophan (5-HTP), also known as oxitriptan, is a naturally occurring amino acid and chemical precursor as well as a metabolic intermediate in the biosynthesis of the neurotransmitter serotonin.

Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells

ActiveUS20050136513A1Reduced and even undetectable efficiencyImprove efficiencySugar derivativesDepsipeptides5-HydroxytryptophanMammalian cell
This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase / tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation.
Owner:THE SCRIPPS RES INST

Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound

This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating CNS disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain.
Owner:DUKE UNIV

Nutritional supplement for the management of weight

Described herein is a low-glycemic nutritional supplement to be incorporated into the diet of an overweight or obese patient comprising low glycemic index ingredients including carbohydrate source, a source of protein, and a source of fat, and further comprising a source of green tea extract, a source of 5-hydroxytryptophan (5-HTP), and a source of chromium. The supplement provides active food-grade ingredients to improve the management weight loss, prevention of weight gain, and a feeling of satiety.
Owner:ADVANCED FUNCTIONAL FOODS INT

Composition and method for reducing lipid storage

InactiveUS20050095233A1Increasing fatty acid oxidationEnhancement of thermogenic futile cycleBiocidePeptide/protein ingredientsLipid storageAdditive ingredient
An orally or parenterally administered composition for reducing the storage of lipids in a human, the composition comprising: an effective amount of hydroxycitric acid; an effective amount of carnitine; an effective amount of biotin; an effective amount of one or more gluconeogenic substrates selected from the group consisting of: aspartate, lactate, glycerol, and a gluconeogenic amino acid or alphaketo analogue thereof; an effective amount of eicosapentanoic acid; and an effective amount of one or more ingredients selected from the group consisting of: medium chain triglycerides (MCT) with fatty acid backbones containing 6 to 14 carbon atoms or their individual fatty acid analogues or metabolic precursors, sesame seeds or derivative products, sesamin and / or its epimer episesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone (7-keto DHEA), green tea extract containing epigallocatechingallate (EGCG), capsaicum, and 5-hydroxytryptophan (5-HTP). The supplement may also be combined with a food, beverage, condiment, spice or salad dressing base to provide a food, beverage, condiment, spice or salad dressing product designed to reduce lipid storage.
Owner:MCCLEARY EDWARD LARRY +2

Dietary Supplement Cognitive Support System

The present invention relates to a nutritional supplement composition, comprising a therapeutically effective amounts of Vitamin C, Vitamin D3, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic acid, Vitamin B12, Pantothenic acid, Calcium, Magnesium, Zinc, Chromium, Sugar, Protein, Acetyl-L-Carnitine, Dimethylaminoethanol complex, Phosphatidylserine complex, L-Glutamine, N-Acetyl-L-Tyrosine, L-Phenylalanine, Taurine, Methionine, Valine, Isoleucine, 5 Hydroxytryptophan, L-Taurine, N-Acetyl-Tyrosine, N-Acetyl-L-Cysteine, Alpha Lipoic Acid, Alpha Glycerylphosphoricholine complex, Bacopa Monnieri extract, Gingko Biloba extract, Passion flower, Lemon Balm, Gotu Kola, Ashwagandha, Choline Bitartrate complex, Panax Ginseng extract, Turmeric, Organic freeze dried fruit juice blends (concord grape, red raspberry, pineapple, cranberry, acai, pomegranate, acerola cherry, bilberry, lingonberry, black currant, aronia, sour cherry, black raspberry), Organic freeze dried greens blends (barley grass, broccoli, beet, carrot, alfalfa, oat), and Protein digestive enzyme blends (Protease 4.5, peptidase, bromelain, protease 6.0, protease 3.0, L planatrum, B bifidum) in a mixture to provide optimal cognitive function.
Owner:FANTZ DAVID R

Fluorescent detection of proteins in polyacrylamide gels

ActiveUS7569130B2Laborious labelingLaborious staining stepElectrolysis componentsChemiluminescene/bioluminescenceSpectroscopyTryptophan
The mechanism of the UV light-induced reaction between the indole moiety of tryptophan and chloroform, and the structure of the modified tryptophan and polypeptides including such modified tryptophan residues. The excited indole moiety, which is formed upon UV light irradiation, emits a solvated electron which initiates a series of events that yield fluorescent derivatives that have CHO group covalently bound to the indole moiety. These derivatives are herein referred to as formyltryptophan, and are relatively stable. Similar reactions are observed when 5-hydroxytryptophan, 5-fluorotryptophan, or N-methylindolacetate are used in place of tryptophan, or when other haloalkanes, such as trichloracetic acid, trichlorethanol, trichlorethane, bromoform, and iodoactetate are used in place of chloroform. The derivatives can be used in a variety of applications in fluorescence spectroscopy, and for nuclear magnetic resonance, X-ray crystallography, infra-red spectroscopy, circular dicroism and mass spectroscopy. Additionally, the UV light-induced reaction between the indole moiety of tryptophan and haloalkanes can be used to prepare derivatives of tryptophan for chemical cross-linking studies of proteins and peptides.
Owner:UNIV TECH INT +1

Fluorescent detection of proteins in polyacrylamide gels

InactiveUS20100089753A1Without laborious labeling and staining stepElectrolysis componentsVolume/mass flow measurementSpectroscopyTryptophan
The mechanism of the UV light-induced reaction between the indole moiety of tryptophan and chloroform, and the structure of the modified tryptophan and polypeptides including such modified tryptophan residues. The excited indole moiety, which is formed upon UV light irradiation, emits a solvated electron which initiates a series of events that yield fluorescent derivatives that have CHO group covalently bound to the indole moiety. These derivatives are herein referred to as formyltryptophan, and are relatively stable. Similar reactions are observed when 5-hydroxytryptophan, 5-fluorotryptophan, or N-methylindolacetate are used in place of tryptophan, or when other haloalkanes, such as trichloracetic acid, trichlorethanol, trichlorethane, bromoform, and iodoactetate are used in place of chloroform. The derivatives can be used in a variety of applications in fluorescence spectroscopy, and for nuclear magnetic resonance, X-ray crystallography, infra-red spectroscopy, circular dicroism and mass spectroscopy. Additionally, the UV light-induced reaction between the indole moiety of tryptophan and haloalkanes can be used to prepare derivatives of tryptophan for chemical cross-linking studies of proteins and peptides.
Owner:UNIV TECH INT +1

Blood pressure reducing and sleeping promoting health-care food

The invention discloses blood pressure reducing and sleeping promoting health-care food. The health-care food comprises oligosaccharide, gamma-aminobutyric acid, theanine, taurine, 5-hydroxytryptophan, minerals and vitamins. The health-care food is reasonable in prescription and rich in nutrients, and can be used for effectively relieving physical and psychological stress, relaxing mind, promoting sleeping and reducing blood pressure.
Owner:NANTONG LICHENG BIOLOGICAL ENG

Comprehensive pharmacologic therapy for treatment of obesity including cysteine

InactiveUS20050065190A1Simple and inexpensive designWithout fear of injury to personsBiocidePeptide/protein ingredientsDiethylpropionVitamin C
The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and / or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.
Owner:FEDERAL LAW ENFORCEMENT DEV SERVICES

Composition for treatment of obesity or generally aiding weight loss in pill, powder or liquid form, by appetite reduction and metabolism increase, comprising: L- phenylalanine, caffeine, and one or more of the group of all forms of 5-hydroxytryptophan and L-tryptophan, all from either natural or synthetic sources

A method of treating a human subject suffering from obesity or who simply desires to lose weight is disclosed, which comprises administering to the subject an effective amount of a compound which enhances serotonin, noradrenaline, and adrenaline activity. The formula is comprised of effective amounts of caffeine, L-phenylalanine, and one or more of L-tryptophan and 5-hydroxytryptophan.
Owner:DYNAPURE NUTRITION

Production process for extracting and preparing high-purity 5-hydroxytryptophan from Griffonia simplicifolia

The invention provides a production process for extracting and preparing high-purity 5-hydroxytryptophan from Griffonia simplicifolia, belonging to the technical content of extracting 5-hydroxytryptophan from plants and solving the problems of low yield, low purity and influence on product quality, low extraction speed and the like due to variegation generated by other pigment in the process of extracting 5-hydroxytryptophan from plants in the prior art. The production process comprises the following steps: using Griffonia simplicifolia produced in Africa as raw material, carrying out supercritical extraction for degreasing, extracting the degreased material for 3-5 times by using water or alcoholic solvents or mixed solution of water and alcoholic solvents; merging the extraction solution, carrying out microfiltration, ultrafiltration, adsorption by using ion exchange resin, elution, vacuum concentration, lower-temperature crystallization, centrifugal separation and microwave drying to obtain high-purity 5-hydroxytryptophan dry powders. The process has the advantages of rapidness, high efficiency, high yield, good quality and the like, and is suitable for large-scale industrial production; and the purity of the obtained product can reach more than 99.5 percent, and the yield is more than 90 percent.
Owner:三明华健生物工程有限公司

Comprehensive pharmacologic therapy for treatment of a dysfunction

InactiveUS20050233008A1Promote resultsHigh expectation of weight lossBiocidePeptide/protein ingredientsDiethylpropionVitamin C
The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and / or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.
Owner:FEDERAL LAW ENFORCEMENT DEV SERVICES

Composition for improving exercise-induced insomnia

InactiveCN106692751AImprove exercise-induced insomniaOrganic active ingredientsNervous disorderMedicineGamma-Aminobutyric acid
The invention discloses a composition comprising melatonin, gamma-aminobutyric acid, instant asparagus powder, platycladi seeds, vitamin B6, 5-hydroxytryptophan, theanine and semen ziziphi spinosae and the like. The composition can remarkably improve exercise-induced insomnia.
Owner:BEIJING COMPETITOR SPORTS SCI & TECH

Nutritional sleep supplement

InactiveUS20150087679A1Facilitate healthy lifestyleBiocideAnimal repellantsNiacinBULK ACTIVE INGREDIENT
Embodiments of the present invention relate to a nutritional sleep supplement having a balanced ratio of nutritional elements to facilitate a healthy lifestyle. In one embodiment, a nutritional sleep supplement has a set of active ingredients, the active ingredients comprising: between 50 mg to 600 mg of 5-Hydroxytryptophan; between 125 mg to 1500 mg of calcium lactate; between 50 mg to 600 mg of citric acid; between 125 mg to 1500 mg of gamma-Aminobutyric acid; between 50 mg to 600 mg of L-theanine; between 25 mg to 300 mg of L-tryptophan; between 45 mg to 540 mg of magnesium glycinate; between 1.25 mg to 15 mg of melatonin; between 8.75 mg to 105 mg of niacin; between 7.5 mg to 90 mg of potassium sorbate; and between 10 mg to 100 mg of pyridoxine.
Owner:HELMI HANY +1

Precursor-directed biosynthesis of 5-hydroxytryptophan

The invention provides compounds, compositions, non-naturally occurring organisms, and methods useful for production of 5-hydroxytryptophan (5-HTP) in a microbial cell. A microbial system which includes at least one microbial cell, such as a bacterial cell or a yeast cell, is genetically engineered to express all or a portion of non-naturally occurring biosynthetic pathway that catalyzes the conversion of a simple carbon source, such as glucose, to 5-HTP. The invention can result in improved titers of 5-HTP and permits low-cost, large scale production. Methods of making and using the genetically engineered cells are also included in the invention.
Owner:UNIV OF GEORGIA RES FOUND INC

Preparation method of levo-5-hydroxytryptophan

The invention provides a preparation method of levo-5-hydroxytryptophan. The method comprises the following steps: performing methyl esterification / ethyl esterification on L-tryptophan to obtain L-tryptophan methyl / ethyl ester hydrochloride, performing dehydrochlorination under the alkaline condition to obtain L-tryptophan methyl / ethyl ester, performing acetylation to obtain N-acetyl-L-tryptophanmethyl / ethyl ester, reducing an indole ring under a triethylsilane-trifluoroacetic acid reduction system, oxidizing 1-position nitrogen of the indole ring under a sodium tungstate-30% hydrogen peroxide system, finally removing acetyl protection group to obtain levo-5-hydroxytryptophan under the acidic condition, further cooling and crystallizing, then enabling mother liquor to pass through a macroporous adsorption resin column, performing concentration, cooling and crystallization, and combining obtained levo-5-hydroxytryptophan crystals. The process has the advantages of being low in price of raw materials, being easy to obtain the raw materials, being simple in reaction operation, being high in yield, being good in product quality, being low in environmental pollution and the like, and is suitable for industrial large-scale production, the purity of the obtained product can achieve 99.2%, and the total yield is above 45%.
Owner:FOSHAN PRIZEN MEDICAL TECH

5-HTP Combination Therapy

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.
Owner:H LUNDBECK AS

Method for extracting 5-hydroxytryptophan

InactiveCN102464602AReduce the frequency of depigmentationReduce the number of crystallizationOrganic chemistryAntioxidantIon exchange
The invention relates to a method for extracting 5-hydroxytryptophan. The method has the advantages that: the yield of the product is improved and the energy consumption is reduced because an antioxidant is added to protect and an ion exchange resin and a macroporous resin are combined. The method comprises the following steps of: crushing a raw material, namely griffonia seeds, soaking the raw material into acidic water and sodium pyrosulfite for extraction for 2 to 3 times, wherein the amount of the acidic water and the amount of the sodium pyrosulfite are both 8 to 15 times that of the raw material and the raw material is soaked for 4 to 10 hours at each time, adsorbing the extract by adding the extract into a cation exchange resin column, washing the extract with deionized water until the extract is colorless, eluting the extract with aqueous ammonia (containing 0.1 to 0.3 percent of sodium metabisulfite) of which the concentration is 10 to 15 percent, adjusting the pH value of the eluate to 2 to 4, adsorbing the eluate by adding the eluate into a macroporous resin column, washing the eluate with water until the eluate is neutral, eluting the effective component with 4-6 BV ethanol solution of which the concentration is 40 to 60 percent, collecting the eluate, adding the eluate into active carbon to decolor the eluate, reclaiming the ethanol, concentrating the decoloring liquid until the concentration of the decoloring liquid is 1.4 to 1.6, placing the decoloring liquid until the decoloring liquid is crystallized, filtering the crystal, and drying the crystal to obtain the product. The method is simply operated and is suitable for industrial production.
Owner:苏州宝泽堂医药科技有限公司

Microorganisms for the production of 5-hydroxytryptophan

InactiveUS20150037849A1Cost-efficient productionBacteriaHydrolasesMicroorganismTryptophan hydroxylase
Recombinant microbial cells and methods for producing 5-hydroxytryptophan (5HTP) using such cells are described. More specifically, the recombinant microbial cell comprises an exogenous gene encoding an L-tryptophan hydroxylase, and means for providing tetrahydrobiopterin (THB). Related sequences and vectors for use in preparing such recombinant microbial cells are also described.
Owner:DANMARKS TEKNISKE UNIV

New synthetic method of PET imaging agent L-5-<18>FETP

The invention relates to a new synthetic method of a PET imaging agent L-5-<18>FETP. The method comprises the following steps: (a) carrying out a reaction between 5-hydroxytryptophan and C<1-3>alkylolto obtain a product; carrying out a reaction between the product and di-tert-butyl (i.e. (BOC)2O) to obtain N-BOC-L-5-hydroxytryptophan; (b) fluorizating 1,2-glycol tosylate in the presence of the ions such as potassium carbonate, Kryptate2.2.2 and <18>F<-> to obtain 2-<18F>-fluoroethanol p-toluene sulphonic acid ester (i.e. <18>FCH2CH2OTs); (c) carrying out a reaction between the 2-<18F>-fluoroethanol p-toluene sulphonic acid ester and the alkali metal salt of the N-BOC-L-5-hydroxytryptophan (such as sodium salt) to obtain O-(2-<18F>fluoroethyl)-N-BOC-L-5-hydroxytryptophan; (d) hydrolyzing the O-(2-<18F>fluoroethyl)-N-BOC-L-5-hydroxytryptophan under acidic conditions to remove an amino group and a carboxy protective group and obtain a final product of O-(2-<18F>fluoroethyl)-N-BOC-L-5-hydroxy tryptophan; and (e) purifying the product. The method greatly improves the radiochemical yield, obtains a sufficient quantity of a target product and realizes the clinical application of the target product.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI

Compositions and methods for treating insomnia and other sleep related disorders

The present disclosure is a composition, a method of making the composition and method of using such composition preferably in the form of a dietary supplement that, when administered, is capable of treating insomnia and other sleep-related disorders. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least vitamin B6, chamomile extract, passionflower extract, lemon balm extract, L-Theanine, GABA, 5-Hydroxytryptophan, and melatonin, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule, powder, liquid or tablet.
Owner:SCRIPT ESSENTIALS LLC

Novel extraction and purification technology for 5-hydroxytryptophan

InactiveCN103145602AOrganic chemistryGriffonia simplicifolia5-Hydroxytryptophan
The invention provides a novel extraction and purification technology for 5-hydroxytryptophan. The novel extraction and purification technology mainly comprises the following steps of: (1) squeezing griffonia simplicifolia seeds to remove oil; (2) extracting cake feeds; (3) concentrating an extracting solution, and degreasing; (4) crystallizing a concentration solution; (5) centrifuging crystal substances and drying; and (6) preprocessing crystallizing mother liquor. Especially, the crystallizing mother liquor is treated by four methods, so that scarce resources are effectively utilized, and the yield is increased, and the total yield can be up to 12.5%. An anti-oxidant treatment technology is adopted in squeezing and extraction processes; the novel extraction and purification technology is advanced and unique, has the advantages of mild extraction conditions, high extraction ratio, low production cost, high yield and simple and convenient operation, and is environment-friendly and suitable for industrial production; and raw materials are saved in the whole productive process.
Owner:李玉山
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products